There are 3 papers on CIP2A in aging research: none in people yet, 2 in animals, 1 in cells.
At a glance
The findings reach cells, none yet in people. 2 independent labs in 2 countries.
None of its findings points the other way.
Cells: a single group. Worms or flies, mice and humans: nothing yet.
- 2 independent labs in 2 countries
- Funders: National Natural Science Foundation of China and 7 more
- Animals2
- Cells1
Interventions
1Metformin
downin mouse cells1
1 study
Metformin
downin mouse cells1
Metformin inhibits CIP2A in mouse cells.
Cells
Effects
2HMGA1
upin mouse cells1
1 study
HMGA1
upin mouse cells1
CIP2A increases HMGA1 in mouse cells (by preventing HMGA1 ubiquitination and proteasomal degradation, with OTUD4 recruited).
Cellsby preventing HMGA1 ubiquitination and proteasomal degradation, with OTUD4 recruited
Osteoclast formation
upin mouse cells1
1 study
Osteoclast formation
upin mouse cells1
CIP2A increases osteoclast formation in mouse cells (RANKL-induced BMMs).
CellsRANKL-induced BMMs
Latest
1 paper in 12 monthsResearch Square
CIP2A promotes osteoclastogenesis and postmenopausal bone loss by activating a novel HMGA1–c-Myc–PI3K/AKT axis
Preprint: experiments in micePI3K–AKT signaling